Showing 3,421 - 3,440 results of 4,404 for search '"Clinical trial"', query time: 0.11s Refine Results
  1. 3421

    A review of parameter settings for galvanic vestibular stimulation in clinical applications by Yishai Valter, Yishai Valter, Linda Vataksi, Aaron R. Allred, Jeffrey R. Hebert, Tad T. Brunyé, Tad T. Brunyé, Torin K. Clark, Jorge Serrador, Abhishek Datta, Abhishek Datta

    Published 2025-02-01
    “…We performed a literature search on the PubMed and Embase databases for clinical trials including the term “galvanic vestibular stimulation.” …”
    Get full text
    Article
  2. 3422
  3. 3423

    Use of virtual reality to remotely train healthcare professionals in paediatric emergency tracheostomy skills: protocol for a multi-centre, non-inferiority educational intervention... by Jonathan R. Abbas, Noorulanne Younis, Emily Johnstone, Azita Rajai, Rachel Isba, Antony Payton, Brendan A. McGrath, Neil Tolley, Iain A. Bruce

    Published 2025-01-01
    “…Trial registration Full registration of this study was completed at ClinicalTrials.gov. The registration number is NCT06350708 and was accepted on the 4th April 2024.…”
    Get full text
    Article
  4. 3424

    MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial by Mrinal Gounder, Melissa Johnson, Rebecca S. Heist, Geoffrey I. Shapiro, Sophie Postel-Vinay, Frederick H. Wilson, Elena Garralda, Gerburg Wulf, Caroline Almon, Salah Nabhan, Elia Aguado-Fraile, Peng He, Mathilde Romagnoli, Mohammad Hossain, Rohini Narayanaswamy, Amel Sadou-Dubourgnoux, Michael Cooper, Vasileios Askoxylakis, Howard A. Burris, Josep Tabernero

    Published 2025-01-01
    “…We report results from the first-in-human, phase 1 trial of AG-270/S095033 as monotherapy in patients with advanced malignancies (ClinicalTrials.gov Identifier: NCT03435250). Eligible patients had tumors with homozygous deletion of CDKN2A/MTAP and/or loss of MTAP protein by immunohistochemistry. …”
    Get full text
    Article
  5. 3425

    Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review by Aleksander Jentkiewicz, Esmail Haj Obeid, Jakub Ulrych, Jan Krupa, Maciej Malinowski, Michał Krasowski, Alicja Kalinowska, Wiktoria Pietras, Adrian Kozieł, Zofia Kurek

    Published 2025-02-01
    “…Gastric emptying and insulin secretion are also affected by GLP-1 RAs. Clinical trials consistently demonstrate significant weight loss, positive action on cardiovascular risk and better glycemic control. …”
    Get full text
    Article
  6. 3426

    Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials by Myra Happe, Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F. Kelley, Sarah Kabbani, Srilatha Edupuganti, Allison Beck, Florence Kaltovich, Tamar Murray, Susanna Tsukerman, Derick Carr, Carl Ashman, Daphne A. Stanley, Aurélie Ploquin, Robert T. Bailer, Richard Schwartz, Fatim Cham, Allan Tindikahwa, Zonghui Hu, Ingelise J. Gordon, Nadine Rouphael, Katherine V. Houser, Emily E. Coates, Barney S. Graham, Richard A. Koup, John R. Mascola, Nancy J. Sullivan, Merlin L. Robb, Julie A. Ake, Kirsten E. Lyke, Mark J. Mulligan, Julie E. Ledgerwood, Hannah Kibuuka, the VRC 208 and RV 422 study team

    Published 2024-03-01
    “…We investigated the safety and immunogenicity of a heterologous prime-boost regimen involving a chimpanzee adenovirus 3 vectored Ebola vaccine [either monovalent (cAd3-EBOZ) or bivalent (cAd3-EBO)] prime followed by a recombinant modified vaccinia virus Ankara EBOV vaccine (MVA-EbolaZ) boost in two phase 1/1b randomized open-label clinical trials in healthy adults in the United States (US) and Uganda (UG). …”
    Get full text
    Article
  7. 3427

    Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect by Swetha Reddi, Liliia Senyshyn, Maryam Ebadi, Daniel Podlesny, Samuel S. Minot, Ted Gooley, Amanda J. Kabage, Geoffrey R. Hill, Stephanie J. Lee, Alexander Khoruts, Armin Rashidi

    Published 2025-01-01
    “…FMT is a holistic microbiota restoration approach that can be performed as a precision therapeutic. ClinicalTrials.gov identifier NCT06026371…”
    Get full text
    Article
  8. 3428

    New drugs for acute kidney injury by Geoffroy Hariri, Matthieu Legrand

    Published 2025-01-01
    “…These multifaceted approaches offer renewed hope for limiting the incidence and severity of AKI in critically ill patients. Several ongoing clinical trials are evaluating the efficacy of these different strategies and we are facing an exiting time with multiple therapeutic interventions being tested to prevent or treat AKI. …”
    Get full text
    Article
  9. 3429

    Oral nutritional supplements for gastric cancer – the review of current evidence by A. L. Potapov, V. E. Khoronenko, E. V. Gameeva, Zh. V. Khailova, A. D. Dorozhkin, V. Yu. Scoropad

    Published 2021-03-01
    “…Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. …”
    Get full text
    Article
  10. 3430
  11. 3431
  12. 3432
  13. 3433

    Antibacterial activity of biodentine against Enterococcus faecalis: a systematic review by Hasan Subhi, Nashwah Subhi, Salah Alhaidary, Mahmood S. Azeez, Abedelmalek Kalefh Tabnjh, Abedelmalek Kalefh Tabnjh, Abedelmalek Kalefh Tabnjh

    Published 2025-01-01
    “…However, randomized clinical trials with well-designed and robust methodologies are required in order to provide information about its clinical behaviour.…”
    Get full text
    Article
  14. 3434
  15. 3435
  16. 3436

    Pharmacological and structural insights into nanvuranlat, a selective LAT1 (SLC7A5) inhibitor, and its N-acetyl metabolite with implications for cancer therapy by Chunhuan Jin, Xinyu Zhou, Minhui Xu, Hiroki Okanishi, Ryuichi Ohgaki, Yoshikatsu Kanai

    Published 2025-01-01
    “…Nanvuranlat (JPH203/KYT-0353), a LAT1 inhibitor, has shown antitumor activity in preclinical studies and efficacy in biliary tract cancer during clinical trials. This study provides a comprehensive pharmacological characterization of nanvuranlat and its N-acetyl metabolite, including structural insights into their LAT1 interactions. …”
    Get full text
    Article
  17. 3437

    Beta Blocker Therapy in Heart Failure Patients with Active Cocaine Use: A Systematic Review by Baldeep K. Mann, Janpreet S. Bhandohal, Mohammad Saeed, Gerald Pekler

    Published 2020-01-01
    “…PubMed, EMBASE, Web of Science, and Clinical Trials.gov were searched from inception to March 2019 using the Medical Subject Headings (MeSH) terms “cocaine”, “heart failure”, “beta blocker,” and “cardiomyopathy”. …”
    Get full text
    Article
  18. 3438

    Repurposing of phosphodiesterase-5 inhibitor sildenafil as a therapeutic agent to prevent gastric cancer growth through suppressing c-MYC stability for IL-6 transcription by Zhenzhan Zhang, Wuqing Huang, Donghua Huang, Zhou Xu, Qingfeng Xie, Xin Tan, Wenjun He, Weihao Yang, Guoxin Li, Jianguang Ji, Hao Liu

    Published 2025-01-01
    “…The PDE5 inhibitor sildenafil may serve as a promising adjuvant for GC therapy if further randomized clinical trials confirm its efficacy.…”
    Get full text
    Article
  19. 3439

    EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis by Ao Liu, Xiaoming Wang, Lian Wang, Han Zhuang, Liubo Xiong, Xiao Gan, Qian Wang, Guanyu Tao

    Published 2024-11-01
    “…Methods We searched PubMed, Embase, the Cochrane Central Register of Controlled Clinical Trials databases, and several international conferences to identify randomized controlled trials reporting on first-line EGFR-TKI treatments for patients with advanced EGFR-mutated NSCLC. …”
    Get full text
    Article
  20. 3440